MPC1-deficient C2C12 cells were generated by CRISPR and cultured as described (Oonthonpan, Rauckhorst, Gray, Boutron, & Taylor, 2019)
Metallic taste in the hours after injection attributed by community sources to the copper in GHK-Cu
"I have this love-hate relationship with the beam
The tool shows: Comparison cards : mechanism, evidence tier, FDA status, weight loss data, dosing, cost, pros, cons, and side effects Bar chart : average weight loss percentage from pivotal clinical trials Radar chart : multi-dimensional comparison across efficacy, evidence quality, convenience, tolerability, cost, and cardiovascular data Emerging research : next-generation compounds including BRP (Stanford's natural peptide), survodutide, orforglipron, and amycretin Understanding the data Each weight-loss figure traces to one specific trial: about 15% for semaglutide (STEP 1), up to 22.5% for tirzepatide (SURMOUNT-1), and 24.2% for retatrutide, only a phase 2 result